Clinical trials using modified Vaccinia Virus Ankara (MVA) recombinants against HIV, malaria and tumours are currently underway. To keep a European leading role in the future use of MVA, it will be necessary to introduce modifications in the vector to improve its potency as immunogen. The objective of this project is to develop more immogenic MVA vaccines by:
1) better understanding the biology of the virus;
2) deleting virus immunomodulatory proteins;
3) increasing the virus susceptibility to interferons;
4) effectively displaying antigens on the surface of the virus or cells;
5) expressing host cytokines.
The pathogenis and immune response triggered by the modified MVA will be tested in animal models with vectors expressing relevant antigens from HIV, Plasmodium and tumours. These studies will generate more potent MVA vectors for developing future European Vaccines.
Funding SchemeCSC - Cost-sharing contracts
W2 1PG London